These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 8205592)

  • 1. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
    Ramdani A; Mignon M; Samoyeau R
    Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
    Mignon M; Hochlaf S; Forestier S; Ruszniewski P; Vatier J; Joubert-Collin M
    Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
    Hirschowitz BI; Mohnen J; Shaw S
    Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
    Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome.
    Jensen RT; Metz DC; Koviack PD; Feigenbaum KM
    Aliment Pharmacol Ther; 1993; 7 Suppl 1():41-50, discussion 61-6. PubMed ID: 8490079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
    Hirschowitz BI; Mohnen J; Shaw S
    Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
    Hirschowitz BI; Simmons J; Mohnen J
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
    Metz DC; Pisegna JR; Ringham GL; Feigenbaum K; Koviack PD; Maton PN; Gardner JD; Jensen RT
    Dig Dis Sci; 1993 Feb; 38(2):245-56. PubMed ID: 8425437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zollinger-Ellison syndrome: presentation, response to therapy, and outcome.
    Wilcox CM; Seay T; Arcury JT; Mohnen J; Hirschowitz BI
    Dig Liver Dis; 2011 Jun; 43(6):439-43. PubMed ID: 21193359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
    Hirschowitz BI; Haber MM
    Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
    Morocutti A; Merrouche M; Bjaaland T; Humphries T; Mignon M
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1439-44. PubMed ID: 17081164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal].
    Paul G; Ramdani A; Mignon M; Vallot T; Forestier S; Cadiot G; Ruszniewski P; Joubert-Collin M
    Gastroenterol Clin Biol; 1994; 18(8-9):695-701. PubMed ID: 7875436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome.
    Termanini B; Gibril F; Stewart CA; Weber HC; Jensen RT
    Aliment Pharmacol Ther; 1996 Feb; 10(1):61-71. PubMed ID: 8871445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
    Hirschowitz BI; Simmons J; Mohnen J
    Clin Gastroenterol Hepatol; 2005 Jan; 3(1):39-48. PubMed ID: 15645403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J; Laskowiec G
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment].
    Pospaï D; Cadiot G; Forestier S; Ruszniewski P; Coste T; Escourrou J; Mignon M; Gresze
    Gastroenterol Clin Biol; 1998 Oct; 22(10):801-8. PubMed ID: 9854205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.